Panacea Index Logo

Command Palette

Search for a command to run...

Ketogenic and Low FODMAP Diet in Therapeutic Management of a Young Autistic Patient with Epilepsy and Dysmetabolism Poorly Responsive to Therapies: Clinical Response and Effects of Intestinal Microbiota.

International journal of molecular sciences
August 8, 2022
Alexander Bertuccioli et al. (5 authors)
Case ReportsJournal ArticleHuman Study
Study Details

Study Goal

The researchers aimed to determine whether a low-FODMAP diet could improve neurological, metabolic, and intestinal symptoms in a patient with ASD and associated gut microbiota dysbiosis.

Results Summary

The low-FODMAP diet significantly improved neurological, intestinal, and metabolic symptoms, was well-tolerated, and modulated gut microbiota composition by reducing Actinobacteria, Firmicutes, Lactobacilli, and Bifidobacteria while increasing alpha biodiversity and decreasing the Firmicutes/Bacteroidetes ratio.

Population

A 17-year-old girl with ASD, reduced growth, neurological development delay, and intestinal disorders.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (7)
InterventionDirectionEndpointPopulationDosageImpactClaim #
ketogenic diet
decrease
Firmicutes, Bacteroidetes, and Proteobacteria
17-year-old girl affected by ASD
-
provided a reduction
#1
ketogenic diet
increase
intestinal symptoms
17-year-old girl affected by ASD
-
improved
#2
low FODMAPs diet
increase
all neurological, intestinal, and metabolic symptoms
17-year-old girl affected by ASD
-
produced a significant improvement
#3
low FODMAPs diet
decrease
Actinobacteria, Firmicutes, Lactobacilli, and Bifidobacteria
17-year-old girl affected by ASD
-
showed reductions
#4
low FODMAPs diet
increase
alpha biodiversity
17-year-old girl affected by ASD
-
consistently increased
#5
low FODMAPs diet
decrease
Firmicutes/Bacteroidetes ratio
17-year-old girl affected by ASD
-
decreased
#6
low FODMAPs diet
decrease
extent of fermentative dysbiosis
17-year-old girl affected by ASD
-
reducing
#7
Abstract

Autism spectrum disorder (ASD) is often associated with several intestinal and/or metabolic disorders as well as neurological manifestations such as epilepsy (ASD-E). Those presenting these neuropathological conditions share common aspects in terms of gut microbiota composition. The use of microbiota intervention strategies may be an approach to consider in the management of these cases. We describe the case of a 17-year-old girl affected by ASD, reduced growth, neurological development delay, mutations in the PGM1 and EEF1A2 genes (in the absence of clinically manifested disease) and, intestinal disorders such as abdominal pain and diarrhea associated with weight loss. As she demonstrated poor responsiveness to the therapies provided, we attempted two specific dietary patterns: a ketogenic diet, followed by a low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet, with the aim of improving her neurological, metabolic, and intestinal symptoms through modulation of the gut microbiota's composition. The ketogenic diet (KD) provided a reduction in Firmicutes, Bacteroidetes, and Proteobacteria. Although her intestinal symptoms improved, KD was poorly tolerated. On the other hand, the passage to a low FODMAPs diet produced a significant improvement in all neurological, intestinal, and metabolic symptoms and was well-tolerated. The following gut microbiota analysis showed reductions in Actinobacteria, Firmicutes, Lactobacilli, and Bifidobacteria. The alpha biodiversity was consistently increased and the Firmicutes/Bacteroidetes ratio decreased, reducing the extent of fermentative dysbiosis. Gut microbiota could be a therapeutic target to improve ASD-related symptoms. Further studies are needed to better understand the correlation between gut microbiota composition and ASD, and its possible involvement in the physiopathology of ASD.

Medical Subject Headings (MeSH)
AdolescentAutism Spectrum DisorderAutistic DisorderDiet, Carbohydrate-RestrictedDisaccharidesEpilepsyFemaleGastrointestinal MicrobiomeHumansIrritable Bowel SyndromeMonosaccharidesOligosaccharidesPeptide Elongation Factor 1
Study Links
Quality Scores
Safety85
Efficacy90/10
Quality70/10
Citation Metrics
Total Citations8
Citations/Year2.7
Relative Citation Ratio1.25
NIH Percentile58.5%
Research Impact Scores
APT Score0.50
Weight Score2.40
Normalized Score0.84
Related Supplements
Ketogenic and Low FODMAP Diet in Therapeutic Management of a... | Panacea Index